Welcome to our dedicated page for Apollo Comm SEC filings (Ticker: ARI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Apollo Commercial Real Estate Finance’s multi-hundred-page reports can feel like dissecting a term sheet for every hotel, office, and multifamily loan the REIT holds. If you are searching for Apollo Commercial Real Estate Finance insider trading Form 4 transactions or trying to uncover loan-to-value tables buried deep in the 10-K, the complexity is real—and so is the time drain.
Stock Titan solves this problem. Our AI instantly translates dense mortgage schedules into plain language, flags dividend coverage ratios, and pushes alerts the moment an Apollo Commercial Real Estate Finance Form 4 insider transactions real-time filing hits EDGAR. Whether you need the latest Apollo Commercial Real Estate Finance quarterly earnings report 10-Q filing, an Apollo Commercial Real Estate Finance 8-K material events explained, or the Apollo Commercial Real Estate Finance proxy statement executive compensation summary, every document is updated in real time and paired with concise, context-rich notes. Investors often ask, “How do I read the annual report?”—our platform literally answers with an Apollo Commercial Real Estate Finance annual report 10-K simplified overview.
Use these insights to monitor dividend sustainability, compare quarter-over-quarter net interest margins, or spot patterns in Apollo Commercial Real Estate Finance executive stock transactions Form 4. Have a natural question like “understanding Apollo Commercial Real Estate Finance SEC documents with AI” or looking for an Apollo Commercial Real Estate Finance earnings report filing analysis? You’ll find the answers here—without wading through spreadsheets or legal jargon. Complex mortgage REIT disclosures, clarified.
Kiniksa Pharmaceuticals (KNSA) delivered its first profitable Q2. Net product revenue rose 44% YoY to $156.8 m on continued uptake of ARCALYST, lifting six-month sales 56% to $294.6 m. Cost of goods remained low (Q2 COGS 12% of sales), sustaining an ~88% gross margin.
Operating expenses grew 26% to $136.6 m, driven by collaboration spend linked to Genentech and Huadong agreements, but leverage from higher revenue pushed operating income to $20.2 m (-$0.1 m LY). After $5.0 m tax, Q2 net income reached $17.8 m (diluted EPS $0.23) versus a $3.9 m loss a year ago; six-month net income was $26.4 m.
Liquidity strengthened: cash, cash equivalents and U.S.-Treasury investments increased to $307.8 m (up $64 m since year-end) aided by $50.4 m operating cash flow and a $20 m milestone from Huadong. Total assets stand at $661.1 m with equity of $495.0 m; inventory rose to $53.0 m as the company pre-positions ARCALYST supply ahead of a manufacturing tech-transfer approval.
Strategic updates: 1) Redomiciliation from Bermuda to the U.K. completed in 2024; 2) April 2025 termination of the Huadong mavrilimumab license eliminates up to $576 m of potential milestones; 3) Remaining upside includes $570 m in potential Genentech milestones (vixarelimab) and $50 m in ARCALYST sales milestones from Huadong, plus mid-teens royalty streams.
The company expects current liquidity to fund operations for ≥12 months.
FAQ
What is the current stock price of Apollo Comm (ARI)?
What is the market cap of Apollo Comm (ARI)?
What is Apollo Comm (ARI)?
How does Apollo Comm generate revenue?
What are the main property types in Apollo Comm's portfolio?
What differentiates Apollo Comm from other REITs?
How does the company manage risk in its investments?
Where is Apollo Comm primarily located?
What is the core focus of Apollo Comm's investment strategy?
How does Apollo Comm maintain its tax-efficient structure?
